Last reviewed · How we verify
Inactive Substance
An inactive substance serves as a control or placebo with no pharmacological activity.
At a glance
| Generic name | Inactive Substance |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Inactive substances are used in clinical trials as control comparators to establish the efficacy and safety of active investigational drugs. They contain no active pharmaceutical ingredient and produce no intended therapeutic effect, allowing researchers to isolate the true effects of the test drug from placebo response.
Approved indications
Common side effects
Key clinical trials
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- Medication Withdrawal in Stable HF With Improved LVEF (PHASE2, PHASE3)
- Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis (NA)
- Mindfulness And Placebo for Pain (MAPP) Study (NA)
- Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder (PHASE4)
- Safety for Home Administration of Microdose Psilocybin Use (PHASE1)
- Investigation of Psychedelic Effects in Psychoactive Substances (PHASE1)
- Supplementation With Sirtuin Activators in Women With Increased Body Weight (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactive Substance CI brief — competitive landscape report
- Inactive Substance updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI